

## Supplementary material

Kania A, Celejewska-Wójcik N, Żurowska K, Barczyk A. Effectiveness of chronic obstructive pulmonary disease (COPD) treatment with a combination of tiotropium / olodaterol in Polish standard clinical practice as measured by the improvement of the Clinical COPD Questionnaire score: an observational study. *Pol Arch Intern Med.* 2022; 132: 16268. doi:10.20452/pamw.16268

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

**Table S1** Therapeutic success in patients' subgroups, full analysis set.

Subgroups defined based on	Patients achieving therapeutic success in given subgroup, N (%)	<i>p</i> value (Fisher's exact test)
Treatment at baseline		<0.001
ICS, N=15	11 (73.3%)	
LAMA or LABA, N=187	117 (62.6%)	
LAMA+ICS or LABA+ICS, N=87	56 (64.4%)	
no LAMA or LABA or ICS, N=229	191 (83.4%)	
mMRC classification		<0.001
Grade 0-1, N=40	20 (50.0%)	
Grade 2-4, N=478	355 (74.3%)	
Exacerbations or hospitalizations within the last 12 months before initial visit		0.007
0 Exacerbation, N=148	96 (64.9%)	
1 Exacerbation, N=180	127 (70.6%)	
>2 Exacerbations or need for hospitalization, N=190	152 (80.0%)	

Subgroups defined based on	Patients achieving therapeutic success in given subgroup, N (%)	<i>p</i> value (Fisher's exact test)
GOLD group		<0.001
B, N=267	180 (67.4%)	
C, N=40	20 (50.0%)	
D, N=211	175 (82.9%)	
Airflow limitation severity (GOLD grade)*		0.003
1 (mild), N=38	18 (47.4%)	
2 (moderate), N=311	226 (72.7%)	
3 severe, N=138	107 (77.5%)	
4 very severe, N=25	19 (76.0%)	
Age [years]		0.095
≥65, N=329	230 (69.9%)	
<65, N=189	145 (76.7%)	
Duration of COPD		0.159
≤ 2 years, N=173	132 (76.3%)	
>2 years, N=345	243 (70.4%)	

\* N=512

Abbreviations: COPD - chronic obstructive pulmonary disease; GOLD - Global Initiative for Obstructive Lung Disease Criteria; ICS - inhaled corticosteroids; LABA - long-acting beta agonists; LAMA - long-acting muscarinic antagonists; mMRC - Modified Medical Research Council Dyspnea Scale.

**Table S2** Subgroups of patients with PGE score improvement.

Characteristic	PGE improvement by at least 1 (N=358), N (%)	<i>p</i> value (Fisher's exact test)
Age [years]		0.9
<60	113 (31.6%)	
60-70	90 (25.1%)	
70-80	70 (19.6%)	
>80	85 (23.7%)	
GOLD group		<0.001
B	167 (46.6%)	
C	22 (6.1%)	
D	169 (47.2%)	
mMRC classification		0.044
Grade 0-1	22 (6.1%)	
Grade 2-4	336 (93.9%)	
Exacerbations or hospitalizations within the last 12 months before initial visit		<0.001
0 Exacerbation	84 (23.5%)	
1 Exacerbation	124 (34.6%)	
>2 Exacerbations or need for hospitalization	150 (41.9%)	

Abbreviations: COPD - chronic obstructive pulmonary disease; GOLD - Global Initiative for Obstructive Lung Disease Criteria; mMRC - Modified Medical Research Council Dyspnea Scale.

**Table S3** Adverse drug reactions observed during duration of the study.

No.	Patient no.	Age	Sex (F/M)	Adverse event	Therapy required	Action taken	Serious adverse event (yes/no)
1.	4801905	68	F	Asthenia	No	Discontinued	No
				Dyspnoea	No	Discontinued	No
2.	4801915	57	M	Dry throat	No	Discontinued	No
				Oropharyngeal pain	No	Discontinued	No
3.	4801917	73	M	Throat irritation	No	Dose not changed	No
4.	4805101	69	F	Cough	No	Dose not changed	No
5.	4805705	82	F	Cough	No	Dose not changed	No
6.	4805709	77	F	Swelling of eyelid	Yes	Dose not changed	No
				Pharyngeal swelling	Yes	Discontinued	No
				Swelling face	Yes	Dose not changed	No

7.	4805711	70	M	Headache	No	Discontinued	No
				Somnolence	No	Discontinued	No
				Polyuria	No	Discontinued	No
8.	4806805	67	F	Aphonia	No	Discontinued	No
				Dysphonia	No	Discontinued	No

Abbreviations: F/M - female/male.